University of North Carolina at Chapel Hill - North Carolina Cancer Hospital
Welcome,         Profile    Billing    Logout  
 6 Trials 
13 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Thompson, Patrick A
NCT02945800: Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma

Active, not recruiting
2
59
US
nab-Paclitaxel, Abraxane, Gemcitabine, Gemzar
H. Lee Moffitt Cancer Center and Research Institute, National Pediatric Cancer Foundation
Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, Soft Tissue Sarcoma
02/25
02/26
NCT04388839: Evolutionary Therapy for Rhabdomyosarcoma

Recruiting
2
28
US
Vincristine, Cyclophosphamide, Vinorelbine, Navelbine, Actinomycin D, Cosmegen, Cyclophosphamide Pill
H. Lee Moffitt Cancer Center and Research Institute, National Pediatric Cancer Foundation
Rhabdomyosarcoma
08/26
08/27
CA209-9WW, NCT03628209: Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma

Active, not recruiting
1/2
21
US
Nivolumab, Opdivo®, Azacitidine, Vidaza®, Post Treatment Surgery, Standard of Care, Resection of disease
H. Lee Moffitt Cancer Center and Research Institute, Bristol-Myers Squibb
Osteosarcoma, Osteosarcoma in Children, Osteosarcoma Recurrent, Sarcoma
12/24
12/25
NCT04337177: Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors

Recruiting
1
20
US
VAL-413, Orotecan®, Temozolomide, Temodar, Temodal, Temcad, TMZ
Valent Technologies, LLC
Solid Tumors, Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma, Hepatoblastoma, Medulloblastoma
06/25
06/25
NCT01587300: Neuroblastoma Biology Study

Recruiting
N/A
1000
Canada, US
New Approaches to Neuroblastoma Therapy Consortium
Neuroblastoma
12/99
12/99
Cuffee, Juanita
NCT02945800: Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma

Active, not recruiting
2
59
US
nab-Paclitaxel, Abraxane, Gemcitabine, Gemzar
H. Lee Moffitt Cancer Center and Research Institute, National Pediatric Cancer Foundation
Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, Soft Tissue Sarcoma
02/25
02/26
NCT03118986: RCT of Olanzapine for Control of CIV in Children Receiving Highly Emetogenic Chemotherapy

Recruiting
2
200
Canada, US, RoW
Olanzapine, Placebo Oral Tablet
The Hospital for Sick Children, University of California, San Francisco, Children's Mercy Hospital Kansas City, St. Justine's Hospital, Columbia University, Medical University of South Carolina, CancerCare Manitoba, University of North Carolina, Chapel Hill, Nationwide Children's Hospital
Vomiting in Infants and/or Children, Nausea, Hematopoietic System--Cancer, Oncology
03/25
04/25
NCT04388839: Evolutionary Therapy for Rhabdomyosarcoma

Recruiting
2
28
US
Vincristine, Cyclophosphamide, Vinorelbine, Navelbine, Actinomycin D, Cosmegen, Cyclophosphamide Pill
H. Lee Moffitt Cancer Center and Research Institute, National Pediatric Cancer Foundation
Rhabdomyosarcoma
08/26
08/27
NCT04337177: Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors

Recruiting
1
20
US
VAL-413, Orotecan®, Temozolomide, Temodar, Temodal, Temcad, TMZ
Valent Technologies, LLC
Solid Tumors, Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma, Hepatoblastoma, Medulloblastoma
06/25
06/25
NCT04372524: Biomarker Verification in Pediatric Chronic GvHD: ABLE 2.0 / PTCTC GVH 1901 Study

Recruiting
N/A
350
Canada, US
University of British Columbia
Chronic Graft-versus-Host-Disease, Leukemia, Allogeneic Hematopoietic Stem Cell Transplantation, Blood Cancer, Non-Malignant Hematologic and Lymphocytic Disorder
01/24
01/25
Reed, Rachel
NCT04337177: Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors

Recruiting
1
20
US
VAL-413, Orotecan®, Temozolomide, Temodar, Temodal, Temcad, TMZ
Valent Technologies, LLC
Solid Tumors, Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma, Hepatoblastoma, Medulloblastoma
06/25
06/25
MR-BIO, NCT04903236: a Study to Evaluate Changes in MR Imaging and Biological Parameters

Recruiting
N/A
250
Europe
University of Manchester, The Christie NHS Foundation Trust
Cancer
06/25
12/25
RESTORE, NCT04451525: REal-World Analyses of Stroke - Thrombus Occlusion REtrieval

Recruiting
N/A
1000
US
MicroVention Mechanical Thrombectomy Devices as first-line treatment
Microvention-Terumo, Inc.
Acute Ischemic Stroke, Vessel Occlusion, Stroke, Ischemic
12/25
12/25

Download Options